SCYX Scynexis Inc

$SCYX the fact that BARDA committed up to 214 million leads me to believe they got the data readout early, and it's clearly good...

$SCYX — This financing news is hard to overlook for a biotech this size. SCYNEXIS just secured a BARDA contract providing up to $214M in potential non-dilutive funding for antifungal candidate SCY-247. The initial ~$18.5M portion helps advance oral and IV versions toward Phase 2 in invasive candidiasis. Government-funded development significantly changes the financing equation here.

$SCYX may have to sit on this a few days and see what happens after institutions absorb the news. This may be one of those delayed runners. It definitely has a legitimate catalyst. Hanging

$SCYX - SCY770 has been tested in 15 phase 1s and a phase 2 in MASH. The previous company looked at Pk/PD and a number of clinical endpoints. The mechanism of action is well understood and validated $SCYX is INTENTIONALLY doing higher doses b/c the results will give the company important data they can extrapolate to the upcoming P2 in AKPKD. You can model potential outcomes based on the PK/PD they are about to report. This is why it's such a big deal.

$SCYX This is huge news—normally it would mean a 300% to 500% jump; in Scyx's case, I don't know what might happen.

$SCYX Very strange Price movement. Don't you think? We had over 7.5 Million in volume traded on a stock that normally has 110k shares traded. However the price barely moved. Is this institutional acquisition while keeping the prices low?

$SCYX SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

$SCYX Tax loss harvesting underway. Gettem while they are on sale. Pre-Split .53 Interesting & Incredible. $$$$

$SCYX Realistically, what does this go to if GSK announces that they are going to start selling Brexafemme?

$SCYX I like that sc247 is being considered to be used as a prophylactic against IC in high risk patients.( To me that sounds like a heck of a lot of drug needed ) ✍️ Careful about peoples who phoo phoo a good thing like a BARDA award

$SCYX market environment flipped today. Perfect setup for Monday data PR. Going in with > $8 cash/share.

$SCYX One question… why won’t they do a CC with q and a? and don’t tell me gsk zip lock. gsk haven’t lived up to their deal. they should be able to talk to their shareholders.

$SCYX - Dual data readouts dropping tomorrow or Thursday. SCY-770 for ADPKD, in particular, the exciting program here. Poisted to potentiallyh uproot Jynarque which is a billion dollar drug.

$SCYX IMO has sell the news all over it in this bad biotech market. It's a ph1 healthy volunteer PK/food effect study and last year tanked on a similar setup. Anyone telling you differently is trying to manipulate the stock at your expense. The real efficacy data is a year or more out and it's dead money until then. This will close down -25% day of ph1 data guaranteed.

$SCYX -----Invasive candidiasis has become a significant problem, especially in the hospitals. I am surprised that $SCYX is not doing much better on this news. The market cap is low relative to the potential.

$SCYX This suddenly turned very Bullish! 1. Phase 2 results will come out in Q4 likely positive 2. Chance for Brexafemme to be commercialized by GSK over the next year 3. Now we have BARDA cash infusion They just proved that they don't need to solely rely on GSK for their future. They have multiple Irons in the fire now!

$SCYX 3 year cash runway and who knows if additional funding is secured on the way. Looks healthy, and undervalued. beside this, a nice consensus from analysts on the target price of $30+

$SCYX Re: Scy-247 In USA a new fungal brain disease Cladophialophora bantiana *rare but highly lethal black mold that primarily targets the central nervous system, creating abscesses of dead tissue and pus in the brain *four-fold increase in cases *ability to infect individuals with completely healthy immune systems *fatality rate of 60% to 70%. Will SCY-247 Be Helpful? SCY-247 shows promise: *efficacy against C. bantiana remains unproven. • Blood-Brain Barrier Penetration: Unlike many traditional antifungals, SCY-247 has been specifically designed with enhanced tissue penetration • Broad-Spectrum and Anti-Mold Profile: *activity against a wide variety of yeasts and molds • Current Development Status: The U.S. Food and Drug Administration (FDA) has granted SCY-247 Fast Track and Qualified Infectious Disease Product (QIDP) designations. *NDA submission in 2028?

$SCYX Told ya'll. Taking my scalp money to $ELAB We're going to need a bigger rocket.. Pack your space suits 🧑‍🚀 $SOAR $KNRX $SOR

$SCYX fuck this bio market is absolutely terrible. Shorts hammer everything that moves. This shitco should be at $7-8 with this news alone.